Factory Supply 4-Bromo-2-Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7

Kuzadzisa kugutsikana kunotarisirwa nevatengi, isu tine vashandi vedu vakasimba kuti vape rubatsiro rwedu rukuru rwese runosanganisira kusimudzira, kutengesa kwakazara, kuronga, kugadzira, kutonga kwemhando yepamusoro, kurongedza, kuchengetedza uye zvinhu zveFactory Supply 4-Bromo-2 -Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7, Isu takatendeseka uye takazaruka.Isu tinotarisira kushanya kwako uye kumisikidza yakavimbika uye yenguva refu yakamira hukama.
Kuzadzisa kugutsikana kunotarisirwa nevatengi, isu tine vashandi vedu vakasimba kuti vape rubatsiro rwedu rukuru rwese runosanganisira kusimudzira, kutengesa kwakawanda, kuronga, kugadzira, kutonga kwemhando yepamusoro, kurongedza, kuchengetedza uye zvinhu zvekushandisa.China CAS 112704-79-7 uye 112704-79-7, Zvinhu zvedu zvakakunda mukurumbira wakanaka kune imwe neimwe yemarudzi ane hukama.Nokuti kugadzwa kwekambani yedu.isu takasimbirira pamaitiro edu ekugadzira hunyanzvi pamwe neazvino nzira yemazuva ano yekutonga, kukwezva huwandu hukuru hwematarenda mukati meindasitiri iyi.Isu tinoona mhinduro yakanaka semhando yedu yakakosha yehunhu.

1-Bromo-2-methoxy-3-nitro-benzene inoshandiswa sepakati peEltrombopag .
Eltrombopag, yakagadziridzwa naGlaxoSmithKline (GSK) kuUK uye yakazogadziriswa pamwe chete neNovartis kuSwitzerland, ndiyo yekutanga uye yakatenderwa chete mamorekuru madiki asiri peptide TPO receptor agonist munyika.Eltrombopag yakabvumidzwa neUS FDA muna 2008 kurapwa kweidiopathic thrombocytopenic purpura (ITP), uye muna 2014 kurapwa kweaplastic anemia (AA).Ndiwo zvakare mushonga wekutanga wakabvumidzwa neUS FDA kurapwa kweAA mumakore makumi matatu apfuura.
Muna Zvita 2012, US FDA yakabvumidza Eltrombopag kurapwa kwethrombocytopenia muvarwere vane chisingaperi hepatitis C (CHC), kuitira kuti varwere veHepatitis C vane hurombo husina kunaka nekuda kwekuderera kweplatelet count vanogona kutanga nekuchengetedza interferon based standard therapy yezvirwere zvechiropa.Musi waFebruary 3, 2014, GlaxoSmithKline yakazivisa kuti FDA yakapa mukana wekurapa mushonga weEltrombopag kurapwa kwehemopenia muvarwere vane yakanyanya chemicalbook aplastic anemia (SAA) vasina kupindura zvizere kune immunotherapy.Musi waNyamavhuvhu 24, 2015, US FDA yakabvumidza Eltrombopag kurapwa kwethrombocytopenia muvakuru nevana vane makore 1 uye kupfuura vane chronic immune thrombocytopenia (ITP) vasina mhinduro yakakwana kune corticosteroids, immunoglobulins kana splenectomy.Musi waJanuary4, 2018, Eltrombopag yakabvumidzwa kunyorwa muChina kurapwa kwekutanga immune thrombocytopenia (ITP).

Kuzadzisa kugutsikana kunotarisirwa nevatengi, isu tine vashandi vedu vakasimba kuti vape rubatsiro rwedu rukuru rwese runosanganisira kusimudzira, kutengesa kwakazara, kuronga, kugadzira, kutonga kwemhando yepamusoro, kurongedza, kuchengetedza uye zvinhu zveFactory Supply 4-Bromo-2 -Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7, Isu takatendeseka uye takazaruka.Isu tinotarisira kushanya kwako uye kumisikidza yakavimbika uye yenguva refu yakamira hukama.
Factory SupplyChina CAS 112704-79-7 uye 112704-79-7, Zvinhu zvedu zvakakunda mukurumbira wakanaka kune imwe neimwe yemarudzi ane hukama.Nokuti kugadzwa kwekambani yedu.isu takasimbirira pamaitiro edu ekugadzira hunyanzvi pamwe neazvino nzira yemazuva ano yekutonga, kukwezva huwandu hukuru hwematarenda mukati meindasitiri iyi.Isu tinoona mhinduro yakanaka semhando yedu yakakosha yehunhu.